Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
- PMID: 36830015
- PMCID: PMC9952697
- DOI: 10.3390/antiox12020457
Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
Abstract
Breast cancer is the most frequent malignant neoplastic disease in women, with an estimated 2.3 million cases in 2020 worldwide. Its treatment depends on characteristics of the patient and the tumor. In the latter, characteristics include cell type and morphology, anatomical location, and immunophenotype. Concerning this latter aspect, the overexpression of the HER2 receptor, expressed in 15-25% of tumors, is associated with greater aggressiveness and worse prognosis. In recent times some monoclonal antibodies have been developed in order to target HER2 receptor overexpression. Trastuzumab is part of the monoclonal antibodies used as targeted therapy against HER2 receptor, whose major problem is its cardiac safety profile, where it has been associated with cardiotoxicity. The appearance of cardiotoxicity is an indication to stop therapy. Although the pathophysiological mechanism is poorly known, evidence indicates that oxidative stress plays a fundamental role causing DNA damage, increased cytosolic and mitochondrial ROS production, changes in mitochondrial membrane potential, intracellular calcium dysregulation, and the consequent cell death through different pathways. The aim of this review was to explore the use of antioxidants as adjuvant therapy to trastuzumab to prevent its cardiac toxicity, thus leading to ameliorate its safety profile in its administration.
Keywords: antioxidants; cardiotoxicity; immunotherapy; oxidative stress; trastuzumab.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.Oncologist. 2017 Jun;22(6):642-647. doi: 10.1634/theoncologist.2016-0406. Epub 2017 Mar 24. Oncologist. 2017. PMID: 28341761 Free PMC article.
-
Trastuzumab and Doxorubicin Sequential Administration Increases Oxidative Stress and Phosphorylation of Connexin 43 on Ser368.Int J Mol Sci. 2022 Jun 7;23(12):6375. doi: 10.3390/ijms23126375. Int J Mol Sci. 2022. PMID: 35742818 Free PMC article.
-
Cardiotoxicity of novel HER2-targeted therapies.Curr Med Res Opin. 2013 Aug;29(8):1015-24. doi: 10.1185/03007995.2013.807232. Epub 2013 Jun 7. Curr Med Res Opin. 2013. PMID: 23692263 Review.
-
A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.BMC Cancer. 2017 Jun 19;17(1):425. doi: 10.1186/s12885-017-3420-4. BMC Cancer. 2017. PMID: 28629338 Free PMC article. Clinical Trial.
-
Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.Ther Adv Drug Saf. 2014 Aug;5(4):154-66. doi: 10.1177/2042098614529603. Ther Adv Drug Saf. 2014. PMID: 25083270 Free PMC article. Review.
Cited by
-
Anti-apoptotic and antioxidant mechanisms may underlie the abrogative potential of Ocimum gratissimum Linn. Leaf extract and fractions against trastuzumab-induced cardiotoxicity in Wistar rats.Toxicol Rep. 2024 Jan 18;12:200-214. doi: 10.1016/j.toxrep.2024.01.011. eCollection 2024 Jun. Toxicol Rep. 2024. PMID: 38313815 Free PMC article.
-
A recombinant fragment antigen-binding (Fab) of trastuzumab displays low cytotoxic profile in adult human cardiomyocytes: first evidence and the key implication of FcγRIIA receptor.Acta Pharmacol Sin. 2025 Mar;46(3):618-631. doi: 10.1038/s41401-024-01397-3. Epub 2024 Oct 16. Acta Pharmacol Sin. 2025. PMID: 39414958
-
Inhibition of superoxide and iNOS augment cutaneous nitric oxide-dependent vasodilation in non-Hispanic black young adults.Physiol Rep. 2024 Apr;12(8):e16021. doi: 10.14814/phy2.16021. Physiol Rep. 2024. PMID: 38639714 Free PMC article.
-
SGLT2 inhibitors for prevention and management of cancer treatment-related cardiovascular toxicity: a review of potential mechanisms and clinical insights.Cardiooncology. 2025 Feb 11;11(1):15. doi: 10.1186/s40959-024-00284-4. Cardiooncology. 2025. PMID: 39934910 Free PMC article. Review.
-
Nanoparticle-Based Antioxidants in Stress Signaling and Programmed Cell Death in Breast Cancer Treatment.Molecules. 2023 Jul 10;28(14):5305. doi: 10.3390/molecules28145305. Molecules. 2023. PMID: 37513179 Free PMC article. Review.
References
-
- World Health Organization Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2019. [(accessed on 25 December 2022)]. Available online: https://cdn.who.int/media/docs/default-source/gho-documents/global-healt....
-
- World Health Organization Breast Cancer. [(accessed on 25 December 2022)]. Available online: https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous